Icon
+91 94997 68112
Login Register

ALYFTREK - (50MG;20MG;4MG, 125MG;50MG;10MG)

DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM None
50MG;20MG;4MG, 125MG;50MG;10MG
Less Than $1000 mn
None None
None None
None None
ALYFTREK is a combination of deutivacaftor, a CFTR potentiator, tezacaftor, and vanzacaftor indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.
Yes
ALYFTREK Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15 Patent 16 Patent 17 Patent 18 Patent 19 Patent 20 Patent 21 Patent 22 Patent 23 Patent 24 Patent 25 Patent 26 Patent 27 Patent 28 Patent 29 Patent 30 Patent 31 Patent 32 Patent 33 Patent 34
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.